Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871639/0/en/Terns-Pharmaceuticals-Announces-Data-from-Ongoing-Phase-1-Pharmacokinetic-Study-of-Allosteric-BCR-ABL-Inhibitor-TERN-701-in-Adult-Healthy-Volunteers-and-Highlights-Potential-for-Co.html

Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class

Pharmacokinetic data show no clinically significant difference in exposure between fed and fasted dosing

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.